Video yükleniyor...

Video Yüklenemedi

Ana Sayfaya Dön

Why is Low-Carb Science so Freakin' Confusing? 🍟 **Give me 86 sec... Watch this trailer (🔊 on). Brief overview: There is terrible publication and media bias against carbohydrate-restricted and ketogenic diets that ranges from lowered publication standards to distorted headlines to full out lies authorized by peer review. In...

nicknorwitz's profile picture

Nick Norwitz MD PhD

124,244 subscribers

13,459 görüntüleme • 11 ay önce •via X (Twitter)

Sağlık & İyilikBilim & TeknolojiEğitim
LIVE

Anya Rossi• Live Now

Private livecam show

0 Yorum

Yorum bulunmuyor

Orijinal gönderinin yorumları burada görünecek

Benzer Videolar

Gene Editing For LDL Lowering in 5 minutes 👇 I’d appreciate if those interested in the new VERVE-102 / PCSK9 Gene Editing for Cholesterol research take 5 minutes to hear me out on why this is a breakthrough. People are missing key details and the bigger story. Cc Dave Feldman Austin Dudzinski, PharmD, BCACP Abud Bakri MD NEJM Dr. David Ludwig Dr David Unwin Louisa Nicola Hundred Health Darius Sharpe Dr Shawn Baker 🥩 Jan Ellison Baszucki Bret Scher, MD Benjamin Bikman Eric Rodgers
5:02

Gene Editing For LDL Lowering in 5 minutes 👇 I’d appreciate if those interested in the new VERVE-102 / PCSK9 Gene Editing for Cholesterol research take 5 minutes to hear me out on why this is a breakthrough. People are missing key details and the bigger story. Cc Dave Feldman Austin Dudzinski, PharmD, BCACP Abud Bakri MD NEJM Dr. David Ludwig Dr David Unwin Louisa Nicola Hundred Health Darius Sharpe Dr Shawn Baker 🥩 Jan Ellison Baszucki Bret Scher, MD Benjamin Bikman Eric Rodgers

Nick Norwitz MD PhD

13,537 görüntüleme • 4 ay önce

The Most Stunning Discovery About Mitochondria & Heart Health! 🤯 I can't help but post this full video to X! Anyone interested in metabolism NEEDS to see this! Please 🙏: Just watch the first minute and see if you aren't getting goosebumps! TL;DR: Mitochondria are traded between cells and among organs in a complex mitochondrial economy! This alters energy balance and can even save you from a heart attack! (No joke!) cc Benjamin Bikman Martin Picard Dave Feldman Andrew Koutnik, Ph.D. Austin Dudzinski, PharmD, BCACP Andrew D. Huberman, Ph.D. Dr. David Ludwig Metabolic Mind and anyone who gets excited about metabolic health science!!! And if you're curious and want more like this, don't miss the Nuance November promotions happening at #StayCurious Metabolism 👇👇👇
14:14

The Most Stunning Discovery About Mitochondria & Heart Health! 🤯 I can't help but post this full video to X! Anyone interested in metabolism NEEDS to see this! Please 🙏: Just watch the first minute and see if you aren't getting goosebumps! TL;DR: Mitochondria are traded between cells and among organs in a complex mitochondrial economy! This alters energy balance and can even save you from a heart attack! (No joke!) cc Benjamin Bikman Martin Picard Dave Feldman Andrew Koutnik, Ph.D. Austin Dudzinski, PharmD, BCACP Andrew D. Huberman, Ph.D. Dr. David Ludwig Metabolic Mind and anyone who gets excited about metabolic health science!!! And if you're curious and want more like this, don't miss the Nuance November promotions happening at #StayCurious Metabolism 👇👇👇

Nick Norwitz MD PhD

31,455 görüntüleme • 11 ay önce

🚨BIG NEWS: $50M Investment to End America's Health Crisis!🚨 🔬I'm Andrew Koutnik, PhD in Nutrition, Metabolism & Diabetes—and a patient living with an irreversible chronic metabolic disease. Thrilled to advise the NEW Coalition for Metabolic Health, LAUNCHED to REVERSE our chronic disease epidemic! Our 4 BOLD objectives: 1⃣Push policy shifts for science-based nutrition guidelines, research, screenings & insurance. 2⃣Fund unbiased research to empower docs & public with real metabolic insights. 3⃣Educate providers, policymakers & YOU on metabolism's power to prevent/reverse disease. 4⃣Incorporate therapeutic nutrition in everyday care via key partnerships. 👉Join the revolution: #MetabolicHealth #ReverseChronicDisease Metabolic Mind Jan Ellison Baszucki Bret Scher, MD Dr. David Ludwig Dominic D'Agostino Benjamin Bikman DoctorTro
1:23

🚨BIG NEWS: $50M Investment to End America's Health Crisis!🚨 🔬I'm Andrew Koutnik, PhD in Nutrition, Metabolism & Diabetes—and a patient living with an irreversible chronic metabolic disease. Thrilled to advise the NEW Coalition for Metabolic Health, LAUNCHED to REVERSE our chronic disease epidemic! Our 4 BOLD objectives: 1⃣Push policy shifts for science-based nutrition guidelines, research, screenings & insurance. 2⃣Fund unbiased research to empower docs & public with real metabolic insights. 3⃣Educate providers, policymakers & YOU on metabolism's power to prevent/reverse disease. 4⃣Incorporate therapeutic nutrition in everyday care via key partnerships. 👉Join the revolution: #MetabolicHealth #ReverseChronicDisease Metabolic Mind Jan Ellison Baszucki Bret Scher, MD Dr. David Ludwig Dominic D'Agostino Benjamin Bikman DoctorTro

Andrew Koutnik, Ph.D.

29,638 görüntüleme • 1 yıl önce

🥩Full Video: Red Meat and Type 2 Diabetes🥩 2 major studies have recently been published, claiming that red meat is linked to Type 2 Diabetes. The media has been grilling this story, creating a lot of confusion. But are these headlines really worth chewing over? In my latest video, which I'm releasing in full form on X, as well as on YouTube, I break down the serious limitations of these studies and explain why giving up red meat to prevent diabetes is not a fruitful endeavor I encourage you to watch the full video, if you have 12 min. This isn't about loving meat or conspiracy theories. It's about intellectual integrity and deep thought. #RedMeat #Type2Diabetes #DietFacts #HealthMyths #NutritionResearch Will also have more to say in upcoming Metabolic Mind podcast with Bret Scher, MD Jan Ellison Baszucki Benjamin Bikman Simon Hill MSc, BSc Dr Shawn Baker 🥩 Dominic D'Agostino Matthew A. Nehs Dave Danna Dr David Unwin Dave Feldman Dr Rupy Aujla Adrian Soto-Mota Eric Topol
12:02

🥩Full Video: Red Meat and Type 2 Diabetes🥩 2 major studies have recently been published, claiming that red meat is linked to Type 2 Diabetes. The media has been grilling this story, creating a lot of confusion. But are these headlines really worth chewing over? In my latest video, which I'm releasing in full form on X, as well as on YouTube, I break down the serious limitations of these studies and explain why giving up red meat to prevent diabetes is not a fruitful endeavor I encourage you to watch the full video, if you have 12 min. This isn't about loving meat or conspiracy theories. It's about intellectual integrity and deep thought. #RedMeat #Type2Diabetes #DietFacts #HealthMyths #NutritionResearch Will also have more to say in upcoming Metabolic Mind podcast with Bret Scher, MD Jan Ellison Baszucki Benjamin Bikman Simon Hill MSc, BSc Dr Shawn Baker 🥩 Dominic D'Agostino Matthew A. Nehs Dave Danna Dr David Unwin Dave Feldman Dr Rupy Aujla Adrian Soto-Mota Eric Topol

Nick Norwitz MD PhD

44,420 görüntüleme • 2 yıl önce

$50 million! That’s the size of a new privately funded donation by the Baszucki Family to launch the Metabolic Health Coalition, a group of scientists and healthcare professionals committed to addressing the root causes of our metabolic health crisis. As both a PhD scientist and new MD and chronic disease patient, this hits home for me. Because one thing I know for certain: the system we’ve built isn’t designed to prioritize metabolic health. It’s optimized for treatments that maintain the business model—pharmaceuticals, procedures, and quick fixes—not long-term root-cause solutions. 🚨This coalition is different. It’s a move toward unbiased research and widespread education—for both clinicians and patients. It’s a serious effort to bring logic, science, and systems-level change to a crisis that’s been swept under the rug for too long. It’s sad that we need disruption, and that true change is being built of the backs of people like me and my friends and colleagues who became passionate about metabolic health because we or a loved one suffered in a dysfunction system. 🚨But that sad truth is also the reason this metabolic health movement is so robust. Enough have suffered. Let’s shake things up. 1⃣First, follow Coalition for Metabolic Health for further updates. 2⃣Then, check out the metabolic health coalition website (👇) 3⃣Finally, share if you care *Some members of the scientific advisory board and supporting experts you may know and love... Benjamin Bikman Dominic D'Agostino Andrew Koutnik, Ph.D. Georgia Ede MD Dr. David Ludwig Chris Palmer, MD and many more... Ht/ David Baszucki Jan Ellison Baszucki 🙏
1:40

$50 million! That’s the size of a new privately funded donation by the Baszucki Family to launch the Metabolic Health Coalition, a group of scientists and healthcare professionals committed to addressing the root causes of our metabolic health crisis. As both a PhD scientist and new MD and chronic disease patient, this hits home for me. Because one thing I know for certain: the system we’ve built isn’t designed to prioritize metabolic health. It’s optimized for treatments that maintain the business model—pharmaceuticals, procedures, and quick fixes—not long-term root-cause solutions. 🚨This coalition is different. It’s a move toward unbiased research and widespread education—for both clinicians and patients. It’s a serious effort to bring logic, science, and systems-level change to a crisis that’s been swept under the rug for too long. It’s sad that we need disruption, and that true change is being built of the backs of people like me and my friends and colleagues who became passionate about metabolic health because we or a loved one suffered in a dysfunction system. 🚨But that sad truth is also the reason this metabolic health movement is so robust. Enough have suffered. Let’s shake things up. 1⃣First, follow Coalition for Metabolic Health for further updates. 2⃣Then, check out the metabolic health coalition website (👇) 3⃣Finally, share if you care *Some members of the scientific advisory board and supporting experts you may know and love... Benjamin Bikman Dominic D'Agostino Andrew Koutnik, Ph.D. Georgia Ede MD Dr. David Ludwig Chris Palmer, MD and many more... Ht/ David Baszucki Jan Ellison Baszucki 🙏

Nick Norwitz MD PhD

21,262 görüntüleme • 1 yıl önce

What if We're Using GLP-1 Medications All Wrong? Drugs like Ozempic, Wegovy, and Mounjaro are transforming the landscape of medical weight loss, but could their side effects be a sign that we’re not harnessing their full therapeutic potential? In this eye-opening conversation, Dr. Ben Bikman (Benjamin Bikman), metabolic health researcher and professor at BYU, joins Dr. Bret Scher (Bret Scher, MD) to explore a powerful new framework: using GLP-1 medications at low doses and for short durations to help curb carbohydrate cravings, break addictive eating cycles, and support long-term metabolic health. Rather than prescribing high doses indefinitely, Dr. Bikman proposes a more targeted approach: - Microdosing GLP-1s to enhance satiety and reduce cravings for processed carbs - Using the medication as a temporary metabolic tool to support transitions to lower-carb diets - Reducing long-term risks such as muscle loss, mood changes, and diminishing effectiveness - Emphasizing the importance of habit change, insulin regulation, and muscle preservation This conversation reimagines GLP-1s not as a lifelong solution, but as a catalyst for sustainable, low-insulin lifestyles, aligned with ketogenic and metabolic therapies. 📌 Could a 90-day microdosing protocol replace years of medication? Learn how this metabolic-first strategy could empower patients to reclaim their health, without becoming dependent on medication for life. #GLP1 #Ozempic #Wegovy #Mounjaro #BenBikman #MetabolicHealth #Microdosing #InsulinResistance #LowCarbDiet #KetogenicTherapy #MedicalWeightLoss #BretScher #MetabolicMind Expert Featured: Dr. Benjamin Bikman Benjamin Bikman Papers/Articles Mentioned: Follow our channel for more information and education from Bret Scher, MD, FACC, including interviews with leading experts in Metabolic Psychiatry. Learn more about metabolic psychiatry and find helpful resources at Timestamps: 0:00 - What if we’re using GLP-1s all wrong? 1:40 - Dr. Benjamin Bikman’s interest in metabolic health and GLP-1s 3:20 - Unexpected side effect of GLP-1s 5:26 - Are GLP-1s actually beneficial? 10:55 - The difference between “weight loss” and metabolic health 15:10 - The role of cravings and satiety signals 19:58 - Dr. Bikman’s ideal use of GLP-1s 24:14 - “Self-discipline in a syringe” 25:11 - Are all weight loss interventions beneficial? 27:20- New studies examining microdosing GLP-1s 32:12 - Learn more about Dr. Bikman
32:55

What if We're Using GLP-1 Medications All Wrong? Drugs like Ozempic, Wegovy, and Mounjaro are transforming the landscape of medical weight loss, but could their side effects be a sign that we’re not harnessing their full therapeutic potential? In this eye-opening conversation, Dr. Ben Bikman (Benjamin Bikman), metabolic health researcher and professor at BYU, joins Dr. Bret Scher (Bret Scher, MD) to explore a powerful new framework: using GLP-1 medications at low doses and for short durations to help curb carbohydrate cravings, break addictive eating cycles, and support long-term metabolic health. Rather than prescribing high doses indefinitely, Dr. Bikman proposes a more targeted approach: - Microdosing GLP-1s to enhance satiety and reduce cravings for processed carbs - Using the medication as a temporary metabolic tool to support transitions to lower-carb diets - Reducing long-term risks such as muscle loss, mood changes, and diminishing effectiveness - Emphasizing the importance of habit change, insulin regulation, and muscle preservation This conversation reimagines GLP-1s not as a lifelong solution, but as a catalyst for sustainable, low-insulin lifestyles, aligned with ketogenic and metabolic therapies. 📌 Could a 90-day microdosing protocol replace years of medication? Learn how this metabolic-first strategy could empower patients to reclaim their health, without becoming dependent on medication for life. #GLP1 #Ozempic #Wegovy #Mounjaro #BenBikman #MetabolicHealth #Microdosing #InsulinResistance #LowCarbDiet #KetogenicTherapy #MedicalWeightLoss #BretScher #MetabolicMind Expert Featured: Dr. Benjamin Bikman Benjamin Bikman Papers/Articles Mentioned: Follow our channel for more information and education from Bret Scher, MD, FACC, including interviews with leading experts in Metabolic Psychiatry. Learn more about metabolic psychiatry and find helpful resources at Timestamps: 0:00 - What if we’re using GLP-1s all wrong? 1:40 - Dr. Benjamin Bikman’s interest in metabolic health and GLP-1s 3:20 - Unexpected side effect of GLP-1s 5:26 - Are GLP-1s actually beneficial? 10:55 - The difference between “weight loss” and metabolic health 15:10 - The role of cravings and satiety signals 19:58 - Dr. Bikman’s ideal use of GLP-1s 24:14 - “Self-discipline in a syringe” 25:11 - Are all weight loss interventions beneficial? 27:20- New studies examining microdosing GLP-1s 32:12 - Learn more about Dr. Bikman

Metabolic Mind

20,561 görüntüleme • 1 yıl önce

This is—without a doubt—the longest I’ve ever sat on a video before releasing it. Because once I open this Pandora’s box, there’s no closing it. 🚨Full Video: In this video, I share my personal decision to walk around with an LDL of 574 mg/dl and a total cholesterol over 700. But this isn’t about one biomarker, or one study. Decisions about whether to act, when to act, and how to act aren’t simple math problems. Individual complexity and thoughtful consideration can turn what looks like a straightforward equation into something far more nuanced. 🚨This video isn’t about telling you what to think—it’s about showing you how I think. It’s not about dogma or conspiracy. It’s about authenticity, transparency, and the kind of nuanced conversations we need to have if we’re going to approach this topic responsibly. And I say that without irony. If you watch all the way through—rather than jumping to conclusions—you might be surprised by where I land… and what I’m planning next. We don't need to agree. We do need to be willing to keep our eyes, ears, and hearts open to new data and divergent opinions. cc Dave Feldman Adrian Soto-Mota Bret Scher, MD Dr Aseem Malhotra Jan Ellison Baszucki Metabolic Mind Coalition for Metabolic Health Austin Dudzinski, PharmD, BCACP Eric Rodgers Andrew Koutnik, Ph.D. Peter Attia (I'm sure we'll have a productive and cordial chat one day)
0:57

This is—without a doubt—the longest I’ve ever sat on a video before releasing it. Because once I open this Pandora’s box, there’s no closing it. 🚨Full Video: In this video, I share my personal decision to walk around with an LDL of 574 mg/dl and a total cholesterol over 700. But this isn’t about one biomarker, or one study. Decisions about whether to act, when to act, and how to act aren’t simple math problems. Individual complexity and thoughtful consideration can turn what looks like a straightforward equation into something far more nuanced. 🚨This video isn’t about telling you what to think—it’s about showing you how I think. It’s not about dogma or conspiracy. It’s about authenticity, transparency, and the kind of nuanced conversations we need to have if we’re going to approach this topic responsibly. And I say that without irony. If you watch all the way through—rather than jumping to conclusions—you might be surprised by where I land… and what I’m planning next. We don't need to agree. We do need to be willing to keep our eyes, ears, and hearts open to new data and divergent opinions. cc Dave Feldman Adrian Soto-Mota Bret Scher, MD Dr Aseem Malhotra Jan Ellison Baszucki Metabolic Mind Coalition for Metabolic Health Austin Dudzinski, PharmD, BCACP Eric Rodgers Andrew Koutnik, Ph.D. Peter Attia (I'm sure we'll have a productive and cordial chat one day)

Nick Norwitz MD PhD

138,564 görüntüleme • 11 ay önce

💥The response to yesterday's paper has been UNREAL! My phone hasn't stopped buzzing. If you've been under a rock, here are some highlights in <90 sec 👇 🫀Most participants showed no or minimal progression of coronary plaque 🫀Neither ApoB nor LDL exposure predicted plaque progression 🫀But plaque predicted plaque progression What does this mean, in a phrase: "While this paper doesn't disprove the lipid heart hypothesis, it does help expose a major blindspot." There will be a LOT more coming soon... I promise you that... #Cholesterol #LDL #KetoDiet #ApoB #CAC #CCTA #LMHR #LEM #SaturatedFat #HeartHealth #MetabolicHealth cc Dave Feldman Dr Aseem Malhotra Joseph Everett (WIL) Jan Ellison Baszucki Metabolic Mind Also not, this is not a one off. There have been 10+ papers leading to this moment... and we are just getting warmed up... PMID: 40192608, Plaque Begets Plaque. ApoB does not: Longitudinal data from the KETO-CTA trial PMID: 39372369, Carbohydrate restriction-induced elevations in LDL-cholesterol and atherosclerosis: The KETO trial PMID: 38237807, Increased LDL cholesterol in adults with normal but not high body weight: a meta-analysis PMID: 35629964, The Lipid Energy Model: reimagining lipoprotein function in the context of carbohydrate-restricted diets PMID: 35106434, Elevated LDL-cholesterol with a carbohydrate-restricted diet: evidence for a “lean mass hyper-responder” phenotype
1:28

💥The response to yesterday's paper has been UNREAL! My phone hasn't stopped buzzing. If you've been under a rock, here are some highlights in <90 sec 👇 🫀Most participants showed no or minimal progression of coronary plaque 🫀Neither ApoB nor LDL exposure predicted plaque progression 🫀But plaque predicted plaque progression What does this mean, in a phrase: "While this paper doesn't disprove the lipid heart hypothesis, it does help expose a major blindspot." There will be a LOT more coming soon... I promise you that... #Cholesterol #LDL #KetoDiet #ApoB #CAC #CCTA #LMHR #LEM #SaturatedFat #HeartHealth #MetabolicHealth cc Dave Feldman Dr Aseem Malhotra Joseph Everett (WIL) Jan Ellison Baszucki Metabolic Mind Also not, this is not a one off. There have been 10+ papers leading to this moment... and we are just getting warmed up... PMID: 40192608, Plaque Begets Plaque. ApoB does not: Longitudinal data from the KETO-CTA trial PMID: 39372369, Carbohydrate restriction-induced elevations in LDL-cholesterol and atherosclerosis: The KETO trial PMID: 38237807, Increased LDL cholesterol in adults with normal but not high body weight: a meta-analysis PMID: 35629964, The Lipid Energy Model: reimagining lipoprotein function in the context of carbohydrate-restricted diets PMID: 35106434, Elevated LDL-cholesterol with a carbohydrate-restricted diet: evidence for a “lean mass hyper-responder” phenotype

Nick Norwitz MD PhD

46,105 görüntüleme • 1 yıl önce

🚀Did your #LDL cholesterol sky-rocket on #keto? 🧈Were you told it' was because of Saturated Fat? 🚨NEW META OF 41 RCTs just busted that MYTH! 3 Main findings 👉 In studies with 'lean' BMI ( 35), LDL-C ⬇️ 💥BOOM, there's a money shot!💥 👉 Inverse association between BMI and LDL-C 👉 BMI dominates over saturated fat, which has comparatively minimal impact; thus, it's more likely having 6-pack abs is a severe risk factor for high LDL-C on #keto, not butter, beef, bacon or cream 🔗PAPER LINK 🔗 - (To share the data love, copy this link to a Quote tweet or original Tweet with your reaction. Please engage!) FULL Video Abstract (7 min): Major props to first-author Adrian Soto-Mota and senior Dr. David Ludwig. These man are humble & kind geniuses that I'm privileged to know and learn under And +100 pts for the #LEM ⚡️ Dave Feldman Of interest to More Plates More Dates Peter Attia @PlantChompers and Walter Willett (if he had a Twitter) Simon Hill MSc, BSc Thomas Dayspring William Cromwell, MD LipoFan Andrew D. Huberman, Ph.D. Dominic D'Agostino Layne Norton, PhD Metabolic Health Summit
3:06

🚀Did your #LDL cholesterol sky-rocket on #keto? 🧈Were you told it' was because of Saturated Fat? 🚨NEW META OF 41 RCTs just busted that MYTH! 3 Main findings 👉 In studies with 'lean' BMI ( 35), LDL-C ⬇️ 💥BOOM, there's a money shot!💥 👉 Inverse association between BMI and LDL-C 👉 BMI dominates over saturated fat, which has comparatively minimal impact; thus, it's more likely having 6-pack abs is a severe risk factor for high LDL-C on #keto, not butter, beef, bacon or cream 🔗PAPER LINK 🔗 - (To share the data love, copy this link to a Quote tweet or original Tweet with your reaction. Please engage!) FULL Video Abstract (7 min): Major props to first-author Adrian Soto-Mota and senior Dr. David Ludwig. These man are humble & kind geniuses that I'm privileged to know and learn under And +100 pts for the #LEM ⚡️ Dave Feldman Of interest to More Plates More Dates Peter Attia @PlantChompers and Walter Willett (if he had a Twitter) Simon Hill MSc, BSc Thomas Dayspring William Cromwell, MD LipoFan Andrew D. Huberman, Ph.D. Dominic D'Agostino Layne Norton, PhD Metabolic Health Summit

Nick Norwitz MD PhD

269,524 görüntüleme • 2 yıl önce

What if everything we thought we knew about cholesterol and heart disease risk… doesn’t apply to everyone? In this episode, world-renowned cardiologist Dr. Matthew Budoff unpacks the results of a landmark one-year study tracking 100 lean, metabolically healthy individuals on a ketogenic diet with extremely elevated LDL levels. Dr. Budoff is the Program Director, Director of Cardiac CT, and the endowed chair of preventive cardiology at The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center. In this interview, Dr. Scher and Dr. Budoff further break down the results of his new publication, which used advanced imaging to demonstrate that LDL cholesterol and ApoB levels are not associated with plaque progression in Lean-Mass Hyper Responders following a #ketogenicdiet. 📊 Surprising insights: • Elevated LDL and ApoB did not predict plaque progression • Some participants with LDLs over 500 showed no plaque at all • A few participants even experienced plaque regression • Existing plaque—not LDL-C or ApoB—did predict plaque accumulation in this population Dr. Budoff explains what these results mean for clinicians, for patients using ketogenic therapy as a medical intervention, and for the broader conversation around cardiovascular disease risk. “It is important that clinicians, along with the general public, are made aware that personalized, data-driven approaches to assessing risk should be considered based on individual conditions,” said Dr. Budoff. “The existence of this phenotype suggests that alternative markers or tests should be used to establish metabolic health in some cases.” 🎬 These exciting new findings are featured in Dave Feldman and Jen Isenhart’s upcoming documentary, The Cholesterol Code, the story of how a software engineer conducts a groundbreaking study on an unusual group of people—lean, healthy individuals whose doctors are convinced they’ll die young. Real stories of healing with ketogenic diets provide a blueprint for using food as powerful medicine. Visit to learn more about the film and to be the first to hear about private screenings and the general release in the fall. Expert Featured: Dr. Matthew Budoff Matthew Budoff MD Resources Mentioned: Plaque Begets Plaque, ApoB Does Not Diagnostic and Preventative Cardiovascular Imaging Center CMEs Mentioned: Managing Major Mental Illness with Dietary Change: The New Science of Hope Brain Energy: The Metabolic Theory of Mental Illness Learn more about metabolic psychiatry and find helpful resources at
19:42

What if everything we thought we knew about cholesterol and heart disease risk… doesn’t apply to everyone? In this episode, world-renowned cardiologist Dr. Matthew Budoff unpacks the results of a landmark one-year study tracking 100 lean, metabolically healthy individuals on a ketogenic diet with extremely elevated LDL levels. Dr. Budoff is the Program Director, Director of Cardiac CT, and the endowed chair of preventive cardiology at The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center. In this interview, Dr. Scher and Dr. Budoff further break down the results of his new publication, which used advanced imaging to demonstrate that LDL cholesterol and ApoB levels are not associated with plaque progression in Lean-Mass Hyper Responders following a #ketogenicdiet. 📊 Surprising insights: • Elevated LDL and ApoB did not predict plaque progression • Some participants with LDLs over 500 showed no plaque at all • A few participants even experienced plaque regression • Existing plaque—not LDL-C or ApoB—did predict plaque accumulation in this population Dr. Budoff explains what these results mean for clinicians, for patients using ketogenic therapy as a medical intervention, and for the broader conversation around cardiovascular disease risk. “It is important that clinicians, along with the general public, are made aware that personalized, data-driven approaches to assessing risk should be considered based on individual conditions,” said Dr. Budoff. “The existence of this phenotype suggests that alternative markers or tests should be used to establish metabolic health in some cases.” 🎬 These exciting new findings are featured in Dave Feldman and Jen Isenhart’s upcoming documentary, The Cholesterol Code, the story of how a software engineer conducts a groundbreaking study on an unusual group of people—lean, healthy individuals whose doctors are convinced they’ll die young. Real stories of healing with ketogenic diets provide a blueprint for using food as powerful medicine. Visit to learn more about the film and to be the first to hear about private screenings and the general release in the fall. Expert Featured: Dr. Matthew Budoff Matthew Budoff MD Resources Mentioned: Plaque Begets Plaque, ApoB Does Not Diagnostic and Preventative Cardiovascular Imaging Center CMEs Mentioned: Managing Major Mental Illness with Dietary Change: The New Science of Hope Brain Energy: The Metabolic Theory of Mental Illness Learn more about metabolic psychiatry and find helpful resources at

Metabolic Mind

10,423 görüntüleme • 1 yıl önce

There’s been a lot of buzz—and confusion—about the new Keto-CTA study, examining plaque progression in Lean Mass Hyper-Responders (LMHRs). Much of the social media debate has centered on whether high LDL on keto is safe or dangerous, driven largely by how to interpret the supplemental table comparing this study to others on LDL and plaque progression. In this episode of the Metabolic Mind Podcast, we sit down with Dr. Matthew Budoff, a world-renowned cardiologist, cardiac CT researcher, and the study's lead investigator, to discuss the the supplemental table, what the plaque markers mean, and how this fits into the discussion of high- vs -low-risk plaque progression. In this episode, we cover: ✅ What PAV (Percent Atheroma Volume) is, what it actually measures, and why it matters ✅ Why a 50% increase in plaque may sound scary, but can be deceiving ✅ The difference between “treatment-naive” and “treated” participants ✅ What the Miami Heart Study comparison reveals about keto, LDL, and plaque ✅ Why LDL alone may not tell the whole story about heart disease risk ✅ How some high-risk individuals may still benefit from statins and other therapies This study doesn’t answer whether keto causes heart disease or not. Instead, it shows that high LDL on a ketogenic diet is not a reliable predictor of plaque progression across all individuals. What is predictive? The presence of existing plaque. 💡 Key takeaway: Relying on surrogate markers of heart disease, like LDL and ApoB, is not the best way to assess heart disease risk in all populations. If you're concerned about how elevated LDL may be affecting your heart health, the best next step is to speak with your doctor about cardiac imaging to directly assess plaque and gain a clearer picture of your individual risk. Expert Featured: - Dr. Matthew Budoff - X: - Resources Mentioned: Plaque Begets Plaque, ApoB Does Not CMEs Mentioned: Managing Major Mental Illness with Dietary Change: The New Science of Hope Brain Energy: The Metabolic Theory of Mental Illness Follow our channel for more information and education from Bret Scher, MD, FACC, including interviews with leading experts in Metabolic Psychiatry. Learn more about metabolic psychiatry and find helpful resources at
32:51

There’s been a lot of buzz—and confusion—about the new Keto-CTA study, examining plaque progression in Lean Mass Hyper-Responders (LMHRs). Much of the social media debate has centered on whether high LDL on keto is safe or dangerous, driven largely by how to interpret the supplemental table comparing this study to others on LDL and plaque progression. In this episode of the Metabolic Mind Podcast, we sit down with Dr. Matthew Budoff, a world-renowned cardiologist, cardiac CT researcher, and the study's lead investigator, to discuss the the supplemental table, what the plaque markers mean, and how this fits into the discussion of high- vs -low-risk plaque progression. In this episode, we cover: ✅ What PAV (Percent Atheroma Volume) is, what it actually measures, and why it matters ✅ Why a 50% increase in plaque may sound scary, but can be deceiving ✅ The difference between “treatment-naive” and “treated” participants ✅ What the Miami Heart Study comparison reveals about keto, LDL, and plaque ✅ Why LDL alone may not tell the whole story about heart disease risk ✅ How some high-risk individuals may still benefit from statins and other therapies This study doesn’t answer whether keto causes heart disease or not. Instead, it shows that high LDL on a ketogenic diet is not a reliable predictor of plaque progression across all individuals. What is predictive? The presence of existing plaque. 💡 Key takeaway: Relying on surrogate markers of heart disease, like LDL and ApoB, is not the best way to assess heart disease risk in all populations. If you're concerned about how elevated LDL may be affecting your heart health, the best next step is to speak with your doctor about cardiac imaging to directly assess plaque and gain a clearer picture of your individual risk. Expert Featured: - Dr. Matthew Budoff - X: - Resources Mentioned: Plaque Begets Plaque, ApoB Does Not CMEs Mentioned: Managing Major Mental Illness with Dietary Change: The New Science of Hope Brain Energy: The Metabolic Theory of Mental Illness Follow our channel for more information and education from Bret Scher, MD, FACC, including interviews with leading experts in Metabolic Psychiatry. Learn more about metabolic psychiatry and find helpful resources at

Metabolic Mind

98,305 görüntüleme • 1 yıl önce

Last night Dr David Unwin was on mainstream news talking about the benefits of reducing carbs for those living with diabetes. The results he gets are amazing. I know it can be replicated by others because I copy what he does in my own clinical practice using David Oliver, Freshwell resources (which are free btw). As a result, in 2024 forty of my patients achieved remission too. The news report featured an endocrinologist Shivani Misra who, at the 4mins 27s timestamp in the video, said: "If someone does a low carb with higher fat what does that mean for their cholesterol and their cardiovascular disease risk? We don't know the answer to this" I'm here to tell you this is a false statement. The research has been done. Let me show you: In 2020 a meta analysis looking at the effects of low carb on CVD risk found: "For total cholesterol there was no significant change in the data corresponding to low-carbohydrate diets lasting 12–23 months and over 24 months" With regards LDL the meta analysis says: "For plasma LDL, as the forest map shows, that there was no significant difference between the low-carbohydrate diet group and the control group at 6–11 months, 12–23 months, and 24 months" All other factors improved (blood pressure, triglycerides, etc) The meta analysis concluded: "In conclusion, the overall effect of a low-carbohydrate diet on cardiovascular risk factors tended to be favorable at less than 6 months and 6–11 months, but after 2 years of a low-carbohydrate diet, there was no significant effect on cardiovascular risk factors" So short term: CVD risk factors are improved, long term, things don't get worse". This mirrors what I see in clinical practice and with myself having been low carb full time since the start of 2020 - all my CVD risk markers are in the normal range. Study source: The reporter also talks about low carb as a "restrictive diet". What's more restrictive: Giving up bagels, bread, sweets and other junk IN FAVOUR OF protein, vegetables etc Or Giving up solid food entirely for a 850kcal liquid diet for months? Despite the latter being far more restrictive it has been rolled out nationally by the NHS. Nothing wrong with this as it works but so does low carb. Why not give patients a choice? The reporter also says Dr Unwins results are just because of the support he provides. Whilst support matters (a lot), this is blatant misinformation. Plenty of studies show that reducing carbs is disproportionately better for those with diabetes than low fat. Here are some: In 2023 Novo Nordisk published a randomized controlled trial comparing low carb to low fat for diabetes. They found: 🩸 Low carb led to the greatest reduction in hba1c 💉 Only the low carb group reduced medications 📉 Low carb had the greatest reduction in triglycerides + higher HDL (LDL was similar) ⚖️ Low carb group lost more weight + more fat spontaneously despite eating more calories 🩸 Systolic blood pressure was lower for low carb The low carb group non significantly raises their LDL but 0.23mmol. The researchers said: "we consider the beneficial effects of low carb to outweigh the minor increase in LDL (0.23mmol) induced by the diet. This is supported by other studies" So low carb is better and CVD risk markers overall improved. Naturally, the study was hidden behind a Paywall. Link: I can hear the skeptics now: "But Mike, this is one study, it's not enough" Ok here's a meta analysis showing that hba1c is directly proportional to the carbs eaten: This meta analysis concluded:
6:38

Last night Dr David Unwin was on mainstream news talking about the benefits of reducing carbs for those living with diabetes. The results he gets are amazing. I know it can be replicated by others because I copy what he does in my own clinical practice using David Oliver, Freshwell resources (which are free btw). As a result, in 2024 forty of my patients achieved remission too. The news report featured an endocrinologist Shivani Misra who, at the 4mins 27s timestamp in the video, said: "If someone does a low carb with higher fat what does that mean for their cholesterol and their cardiovascular disease risk? We don't know the answer to this" I'm here to tell you this is a false statement. The research has been done. Let me show you: In 2020 a meta analysis looking at the effects of low carb on CVD risk found: "For total cholesterol there was no significant change in the data corresponding to low-carbohydrate diets lasting 12–23 months and over 24 months" With regards LDL the meta analysis says: "For plasma LDL, as the forest map shows, that there was no significant difference between the low-carbohydrate diet group and the control group at 6–11 months, 12–23 months, and 24 months" All other factors improved (blood pressure, triglycerides, etc) The meta analysis concluded: "In conclusion, the overall effect of a low-carbohydrate diet on cardiovascular risk factors tended to be favorable at less than 6 months and 6–11 months, but after 2 years of a low-carbohydrate diet, there was no significant effect on cardiovascular risk factors" So short term: CVD risk factors are improved, long term, things don't get worse". This mirrors what I see in clinical practice and with myself having been low carb full time since the start of 2020 - all my CVD risk markers are in the normal range. Study source: The reporter also talks about low carb as a "restrictive diet". What's more restrictive: Giving up bagels, bread, sweets and other junk IN FAVOUR OF protein, vegetables etc Or Giving up solid food entirely for a 850kcal liquid diet for months? Despite the latter being far more restrictive it has been rolled out nationally by the NHS. Nothing wrong with this as it works but so does low carb. Why not give patients a choice? The reporter also says Dr Unwins results are just because of the support he provides. Whilst support matters (a lot), this is blatant misinformation. Plenty of studies show that reducing carbs is disproportionately better for those with diabetes than low fat. Here are some: In 2023 Novo Nordisk published a randomized controlled trial comparing low carb to low fat for diabetes. They found: 🩸 Low carb led to the greatest reduction in hba1c 💉 Only the low carb group reduced medications 📉 Low carb had the greatest reduction in triglycerides + higher HDL (LDL was similar) ⚖️ Low carb group lost more weight + more fat spontaneously despite eating more calories 🩸 Systolic blood pressure was lower for low carb The low carb group non significantly raises their LDL but 0.23mmol. The researchers said: "we consider the beneficial effects of low carb to outweigh the minor increase in LDL (0.23mmol) induced by the diet. This is supported by other studies" So low carb is better and CVD risk markers overall improved. Naturally, the study was hidden behind a Paywall. Link: I can hear the skeptics now: "But Mike, this is one study, it's not enough" Ok here's a meta analysis showing that hba1c is directly proportional to the carbs eaten: This meta analysis concluded:

Mike - Low Carb Dietitian

17,028 görüntüleme • 1 yıl önce